GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Enhabit Inc (FRA:X34) » Definitions » Research & Development

Enhabit (FRA:X34) Research & Development : €0.0 Mil (TTM As of Jun. 2024)


View and export this data going back to 2022. Start your Free Trial

What is Enhabit Research & Development?

Research & Development is the aggregate amount of research and development expenses during the year. Enhabit's Research & Development for the three months ended in Jun. 2024 was €0.0 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Jun. 2024 was €0.0 Mil.


Enhabit Research & Development Historical Data

The historical data trend for Enhabit's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Enhabit Research & Development Chart

Enhabit Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Research & Development
- - - - -

Enhabit Quarterly Data
Dec19 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Enhabit Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Jun. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Enhabit  (FRA:X34) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.


Enhabit Research & Development Related Terms

Thank you for viewing the detailed overview of Enhabit's Research & Development provided by GuruFocus.com. Please click on the following links to see related term pages.


Enhabit Business Description

Traded in Other Exchanges
Address
6688 N. Central Expressway, Suite 1300, Dallas, TX, USA, 75206
Enhabit Inc provides home health and hospice services in the United States. It offers care where patients prefer it: in their homes. It operates business in two segments: home health and hospice. Its home health agencies provide a comprehensive range of Medicare-certified skilled home health services, including skilled nursing, physical, occupational, and speech therapy, medical social work, and home health aide services.

Enhabit Headlines

No Headlines